Abstracts Archive - Page 1411 of 2425 - ACR Meeting Abstracts

Abstract Number: 25 • 2017 Pediatric Rheumatology Symposium
Reliability of the Physician Global Assessment Scores for Determination of Disease Activity Status within the Pediatric Rheumatology Care and Outcomes Improvement Network
Brandt Groh¹, Ottar Kristinsson², Lisabeth V. Scalzi³, C. April Bingham⁴, Ronald Laxer⁵, Cagri Yildirim-Toruner⁶, Esi Morgan⁷, Michelle Batthish⁸, Beth Gottlieb⁹, Julia G. Harris¹⁰, Murray Passo¹¹, Michael Shishov¹² and Sheetal S. Vora¹³, ¹Pediatrics, Penn State Milton S. Hershey Medical Center, Hershey, PA, ²Pediatrics, Penn State Children's Hospital, Hershey, PA, ³Department of Rheumatology, Penn State Hershey Children’s Hospital, Hershey, PA, ⁴Penn State Health Children's Hospital, Hershey, PA, ⁵Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁷Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ⁹Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁰Children's Mercy - Kansas City, Kansas City, MO, ¹¹Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, ¹²Pediatric Rheumatology, Phoenix Children's Hospital, Phoenix, AZ, ¹³Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC
Background/Purpose: Within the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN), the Physician Global Assessment (PhGA) metric is a key determinant of Òclinically inactiveÓ juvenile…
Abstract Number: 107 • 2017 Pediatric Rheumatology Symposium
Children with Relapsing Polychondritis are likely to be seen in the emergency room prior to establishing the diagnosis
Marcela Ferrada¹, Ninet Sinaii², Keith A. Sikora³, Peter C. Grayson⁴, Thomas Christie⁵, Robert Colbert⁴ and James D. Katz⁶, ¹NIAMS, National Institues of Health, Bethesda, MD, ²Clinical Center, National Institutes of Health, Bethesda, MD, ³Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Relapsing Polychondritis Awareness and Support Foundation, Anoka, MN, ⁶NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare immune-mediated disease characterized by recurrent episodes of chondritis. The pathogenesis of RP is poorly understood, and clinical manifestations…
Abstract Number: 76 • 2017 Pediatric Rheumatology Symposium
Applying 2016 MAS Criteria to Systemic onset Juvenile Idiopathic Arthritis Patients with Diagnosis of Macrophage Activation Syndrome
Ezgi Baris^1,2, Edwin Anderson³ and Fatma Dedeoglu¹, ¹Division of Immunology, Rheumatology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Pediatrics, Marmara University, Istanbul, Turkey, ³Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Macrophage activation syndrome (MAS) is the result of uncontrolled systemic inflammation, which can sometimes complicate systemic onset juvenile idiopathic arthritis (SoJIA). MAS classification criteria…
Abstract Number: 154 • 2017 Pediatric Rheumatology Symposium
“Celebrate Ability”: Structured Art Workshop as a Therapeutic Coping Strategy for Patients with Juvenile Idiopathic Arthritis
Anastasia Dropol¹, Michael Lang², Susanne Benseler¹, Tommy Gerschman³, Nicole Johnson³, Jewel Loewen⁴, Nadia Luca¹, Alicia Ponzio², Brian Rusted⁵, Heinrike Schmeling⁶, Rebeka Stevenson³, Leeanne Stringer², Marinka Twilt¹ and Paivi Miettunen³, ¹Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ²University of Calgary, Calgary, AB, Canada, ³Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Pediatrics, University of Calgary, Calgary, AB, Canada, ⁵Fine Arts, University of Calgary, Calgary, AB, Canada, ⁶University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) affects nearly 20,000 Canadian children. Despite success with medications, managing “invisible” symptoms such as pain and fatigue and psychosocial limitations…
Abstract Number: 121 • 2017 Pediatric Rheumatology Symposium
Safety Of Biological Response Modifiers In Childhood Autoimmune Rheumatic Diseases From A Single North Indian Centre
Sujata Sawhney¹, Abhay Shivpuri² and Manjari Agarwal³, ¹Paediatric rheumatology, Senior Consultant, New Delhi, India, ²Division of Pediatric Rheumatology,Institute of Child Health, Post Doctoral Fellow, New Delhi, India, ³Institute of Child Health, Attending Consultant, New Delhi, India
Background/Purpose: Biologic Response modifiers (BRMs) are sparingly used in India due to: cost & concern of infections. We are a tertiary level centre & have…
Abstract Number: 51 • 2017 Pediatric Rheumatology Symposium
The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA
Joost Swart¹, Nico Wulffraat², Sytze de Roock³ and Pieter van Dijkhuizen⁴, ¹Pediatric Rheumatology/ Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²Wilhelmina Children’s Hospital, Utrecht, Netherlands, ³Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: We wondered if with our current physician based strategy we really do reach improvement within 3 months and inactive disease within 12 months in…
Abstract Number: 97 • 2017 Pediatric Rheumatology Symposium
Bortezomib is Efficacious in the Treatment of Refractory Neuropsychiatric SLE with Psychosis
Renee F Modica¹, Kathleen M Vazzana², Natalie Jane Shiff³, Akaluck Thatayatikom³ and Melissa E Elder¹, ¹Department of Pediatrics, University of Florida, Gainesville, FL, ²Pediatrics, University of Florida at Orlando Health Arnold Palmer Hospital for Children, Orlando, FL, ³Pediatrics, University of Florida, Gainesville, FL
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) with psychosis is challenging to treat with refractory cases often requiring prolonged hospitalization due to significant functional impairment and…
Abstract Number: 142 • 2017 Pediatric Rheumatology Symposium
Neutrophils and monocytes in the early inflammatory cascade of systemic onset Juvenile Idiopathic Arthritis
Nienke M. ter Haar¹, Wilco de Jager², Rianne C. Scholman¹, Jenny Meerding¹, Bas Vastert^3,4 and Sytze de Roock⁴, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Dept Immunology, UMC Utrecht, Utrecht, Netherlands, ³Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Systemic onset Juvenile Idiopathic Artritis (sJIA) is an acquired systemic autoinflammatory disease characterized by spiking fever, arthritis and skin rash. Patients display high inflammatory…
Abstract Number: 31 • 2017 Pediatric Rheumatology Symposium
Predicting therapy response to IL-1 blockade in systemic JIA: a biomarker search
Nienke M. ter Haar¹, Rianne C. Scholman¹, Wilco de Jager², Nadia Ryter³, Ariane de Ganck⁴, Dirk Foell⁵, Sytze de Roock⁶ and Bas Vastert⁷, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Dept Immunology, UMC Utrecht, Utrecht, Netherlands, ³BÜHLMANN Laboratories AG, Basel, Switzerland, ⁴Biogazelle NV, Zwijnaarde, Belgium, ⁵Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ⁶Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Systemic onset juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease, characterized by fever, rash and arthritis. The IL-1 and IL-6 pathway are crucial in…
Abstract Number: 159 • 2017 Pediatric Rheumatology Symposium
Preferences and Satisfaction in a Pediatric Multi-specialty Infusion Center
Catherine McDermott &¹, Brian Sohl¹, Lisa M. McGregor², Lisabeth V. Scalzi³ and Barbara E. Ostrov (does not meet authorship criteria)^4,5, ¹Penn State Hershey Medical Center, Hershey, PA, ²Penn State Hershey Children’s Hospital, Hershey, PA, ³Department of Rheumatology, Penn State Hershey Children’s Hospital, Hershey, PA, ⁴Pediatrics, Penn State Hershey Medical Center, Hershey, PA, ⁵Pediatrics, Penn State Hershey Children's Hospital, Hershey, PA
Background/Purpose: Many pediatric rheumatology patients receive infusions in multi-specialty infusion centers (MSICs). There is little data about pediatric patient satisfaction and preferences within MSICs and…
Abstract Number: 28 • 2017 Pediatric Rheumatology Symposium
Dyslipidemia in Juvenile Dermatomyositis
Arya Kadakia¹, Amer Khojah², Gabrielle A. Morgan^3,4, Megan L. Curran⁵, Irwin Benuck⁶, Chinag-Ching Huang¹, Dong Xu⁷ and Lauren M. Pachman^8,9, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁴Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵Pediatric Rheumatology, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, ⁶Division of Cardiology, Northwestern University Feinberg School of Medicine, Department of Pediatrics, Chicago, IL, ⁷Program of Excellence in Cure-Juvenile Myositis (JM) Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁸Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁹Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL
Background/Purpose: Juvenile Dermatomyositis (JDM) is a multisystem pediatric autoimmune disease characterized by chronic inflammation of muscle and skin. Premature atherosclerosis is an important cause of…
Abstract Number: 95 • 2017 Pediatric Rheumatology Symposium
Development of Cognitive Behavioral Therapy (CBT) for Childhood-onset Systemic Lupus Erythematosus (cSLE) Treatment
Jacqueline Warner¹, Erin Moorman¹, Natoshia Cunningham², Kasha Wiley³, Allen Watts³, Susmita Kashikar-Zuck⁴ and Hermine Brunner⁵, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Rheumatology, PRCSG, Cincinnati, OH
Background/Purpose: cSLE can result in considerable decrements in health-related quality of life (HRQOL) for young patients. Youth with cSLE experience a myriad of symptoms, including…
Abstract Number: 101 • 2017 Pediatric Rheumatology Symposium
Defining Active Features of Juvenile Localized Scleroderma
Suzanne Li¹, Xiaohu Li², Elena Pope³, Katie G. Stewart⁴, Gloria Higgins⁵, C. Egla Rabinovich⁶, Kathleen O'Neil⁷, Kathleen Haines⁸, Ronald Laxer⁹, Marilynn Punaro¹⁰, Heidi Jacobe¹¹, Knut Wittkowski¹², Themba Nyirenda¹³, Ivan Foeldvari¹⁴ and Kathryn S. Torok¹⁵, ¹Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ²Mathematical Sciences, Stevens Institute of Technology, Hoboken, NJ, ³Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ⁵Pediatrics, Nationwide Children's Hospital, Columbus, OH, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁷Pediatrics, Indiana University, Indianapolis, IN, ⁸Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁹Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Texas Scottish Rite Hospital for Children, Dallas, TX, ¹¹Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ¹²Rockefeller University, New York, NY, ¹³Hackensack University Medical Center, Hackensack, NJ, ¹⁴Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ¹⁵Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA
Background/Purpose: Juvenile localized scleroderma (jLS) is the most common form of childhood scleroderma. Because of its chronicity and association with extracutaneous involvement, children are at…
Abstract Number: 120 • 2017 Pediatric Rheumatology Symposium
Use Of Thalidomide From A Tertiary Level Pediatric Rheumatology Centre In India
Manjari Agarwal¹, Abhay Shivpuri² and Sujata Sawhney³, ¹Institute of Child Health, Attending Consultant, New Delhi, India, ²Division of Pediatric Rheumatology,Institute of Child Health, Post Doctoral Fellow, New Delhi, India, ³Paediatric rheumatology, Senior Consultant, New Delhi, India
Background/Purpose: Thalidomide is an effective agent for several pediatric rheumatic diseases: Systemic onset Juvenile idiopathic arthritis(SOJIA), Behcet's disease and recalcitrant skin disease in cSLE to…
Abstract Number: 147 • 2017 Pediatric Rheumatology Symposium
Epigenetic and Transcriptomic Profiling of Primary Juvenile Idiopathic Arthritis Patient Cells: Better Understanding of Disease Pathogenesis
Lucas Picavet¹, Janneke Peeters², Sandra Coenen³, Arjan Boltjes⁴, Femke van Wijk⁵, Paul Coffer², Bas Vastert⁶ and Jorg van Loosdregt⁷, ¹Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, ²Center for Molecular Medicine and Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory for Translational Immunity, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Division of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: For many autoimmune diseases, including Juvenile Idiopathic Arthritis (JIA), the molecular mechanisms remain elusive. JIA can be used as a model to study autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].